Analysis of Usage Antihypertensive Drugs in Outpatient Polyclinic PMI Hospital Bogor: a Comparison of Costeffectiveness and Patients Quality Of Life
Hypertension is the main problem in Indonesia and all of the world. The primary goal of hypertension treatment is reduce the total risk of cardiovascular morbidity and mortality. The high prevalence of hypertension and the requirement of medications for prolonged periods, caused the drug- treatment cost represents a major issue in health economics. The aim of this study was to describe patients characteristic when using antihypertensive drugs in polyclinic PMI hospital Bogor, determine the most cost effective drugs for blood pressure reduced output and asses the influence of hypertensive treatments to quality of life, analyzed the relationship between cost effectiveness and quality of life. This research conducted a cross-sectional descriptive study. Analytical study was Cost Effectiveness Analysis (CEA). Data were collected from primary data (using SF-12 questionnaire) and secondary data (receipt, medical record and laboratory financial data). All data analyzed using SPSS for windows version 17. Of the 137 patient, most of them women (52.6%), average age 58.6 ± 11.4 years, range 28 – 87 year, most of the patients (51.1%) with comorbid conditions and combination therapy (50.4%) was used more commonly. Results of this study indicating that the most cost effective drugs for blood pressure reduced output was combination of Beta Blocker (BB) + diuretic. The outcome measures of cost effectiveness and patient quality of life are correlated with one another.
2. Chobanian AV. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC 7 report. JAMA 289. 2003. 2560-72.
3. Perhimpunan Hipertensi Indonesia (PERHI). Pedoman penanganan pasien hipertensi. Jakarta. 2007.
4. Okubadejo NU, Amira CO. Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to International guidelines in a tertiary-care setting. Journal of Hypertension. 2006. 20:894-7.
5. Gregoire JP. Quality of life in hypertension: The SF-12 compared to the SF-36. Can J Clin Pharmacol. 2004. 11(2): 232-8.
6. Departemen Kesehatan RI. Pharmaceutical care untuk penyakit hipertensi. Jakarta: DepartemenKesehatan Republik Indonesia: 2006.
7. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview. J Hypertens. 2003. 21:1055-76. 8. ESH/ESC. Hypertension practice guidelines committee. The task force for the management of arterial hypertension. European Heart Journal. 2007. 28: 1462-1536.
9. Wang R. Impact of hypertension on health-related quality of life in a population- based study in Shanghai, China. Public Health. 2009. 534-9.
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
copy and redistribute the article in any medium or format
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
- NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.